Alizyme(AZM)

Sector:

Pharmaceuticals & Biotechnology

Index:

FTSE Small Cap

Market Cap

£24.87m

Change Today

Price Down-0.50p

Share Price

11.25p

Annual Information Update

RNS Number : 9982X
Alizyme PLC
01 July 2008
 



For Immediate Release

1 JULY 2008




ALIZYME PLC


ANNUAL INFORMATION UPDATE


Alizyme plc (LSE: AZM), CambridgeUK1 July 2008Alizyme Annual Information Update for the period from 1 July 2007 until 30 June 2008.


Alizyme plc ("Alizyme" or the "Company") announces that, in accordance with the requirements of Prospectus Rule 5.2 issued by the Financial Services Authority, and following publication of the Annual Report on 22 April 2008, the following information has been published or made available to the public during the period from 1 July 2007 until 30 June 2008, in compliance with laws and rules dealing with the regulation of securities, issuers of securities and securities markets.


For the purpose of this update, only references to the information are provided. Full copies of each item can be found at the locations specified below. The information referred to in this Annual Information Update was correct at the time it was published but may now be out-of-date.


1. Announcements made via a Regulatory Information Service


All documents listed below were published via a Regulatory Information Service on the dates indicated.


Date of publication    Title

 

27 June 2008                    Alizyme Licenses COLAL-PRED® to Norgine
24 June 2008                    Result of AGM
20 June 2008                    Alizyme to present at 2008 Piper Jaffray Europe Conference
12 June 2008                    Alizyme to present at the 2008 BIO International Convention
09 June 2008                    Notification of Shares
05 June 2008                    Notification of Shares
05 June 2008                    Notification of Shares
20 May 2008                    Interim Management Statement
20 May 2008                    Commencement of Phase II Study for COLAL-PRED® in the US
9 May 2008                      Major Interest in Shares
02 May 2008                    Notification of Shares
30 April 2008                   Notification of Shares
29 April 2008                   Notification of Shares
23 April 2008                   Results from Renzapride
22 April 2008                   2007 Annual Report and Accounts & AGM Notification
17 March 2008                 Major Interest in Shares
17 March 2008                 Major Interest in Shares
17 March 2008                 Major Interest in Shares
11 March 2008                 Voting Rights and Capital
06 March 2008                 Notification of Shareholding
06 March 2008                 Cetilistat Phase III Development Plan
06 March 2008                 Institutional Placing
06 March 2008                 Preliminary Results
19 February 2008             Block Listing
18 February 2008             Major Interest in Shares
01 February 2008             Notification of Shares
25 January 2008               Price Monitoring Extension
24 January 2008               Major Interest in Shares
07 January 2008               Product and Company Update
17 December 2007           Major Interest in Shares
03 December 2007           Voting Rights and Capital
03 December 2007           Strategic Partnership with TSD Japan including a co-development agreement for COLAL-PRED® in Japan
29 November 2007           Webcast - Alizyme Licenses COLAL-PRED® to Prometheus for North America
29 November 2007           Alizyme Licenses COLAL-PRED® to Prometheus for North America
07 November 2007           Major Interest in Shares
31 October 2007               Notification of Shares
16 October 2007               Major Interest in Shares
10 October 2007               Phase III Clinical Product Development Update
24 September 2007           Major Interest in Shares
24 September 2007           Major Interest in Shares
16 August 2007                Holding(s) in Company
15 August 2007                Blocklisting
15 August 2007                Blocklisting
24 July 2007                     Notification of Shares
19 July 2007                     Interim Results
13 July 2007                     Notification: Interim Results
02 July 2007                     Annual Information Update

 


Copies of the documents published via a Regulatory Information Service may be obtained from the Regulatory News Service provided by the London Stock Exchange (http://www.londonstockexchange.com/en-gb/pricesnews/marketnews/) and any related documents are available at the UK Listing Authority's Document Viewing Facility, Financial Services Authority, 25 The North Colonnade, Canary Wharf, London E14 5HS, UK.


Copies of the documents published via a Regulatory Information Service may also be obtained from the Company's website at www.alizyme.com.



2. Documents filed at Companies House


The Company has submitted filings to Companies House in relation to the annual return made up to 22 February 2008the annual report and accounts for the year ended 31 December 2007the allotment of shares and ordinary and special resolutions passed at the Company's Annual General Meeting on 24 June 2008.


Electronic copies of these documents can be purchased from Companies House via its website at www.companies-house.gov.uk, and hard copies can be obtained from Companies House, Crown Way, Cardiff CF14 3UZUK.



The Company's Annual Report and Accounts 2007 (published on 22 April 2008) and Interim Report 2007 (published on 1July 2007) can be found on the Company's website, as can the Interim Results Announcement for the six months ended 30 June 2007 (published on 1July 2007and the Preliminary Results for the year ended 31 December 2007 (published on 6 March 2008). The Company's website is www.alizyme.com.


Copies of all documents referred to above are also available for inspection at the Company's registered office (Granta Park, Great Abington, CambridgeCB21 6GXUnited Kingdom) during normal business hours or by request from the Company Secretary.


For further information, please contact:


David Campbell, Company Secretary

ALIZYME plc                                                               Tel No: + 44 (0)1223 896000


Further information on Alizyme can be found on the Company's website: www.alizyme.com


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AIUBGGDRXGGGGIB

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Digital Look have been voted
"Best Research and Information Provider"

4th Floor, Bankside House, 107 Leadenhall Street, London EC3A 4AF.
Registered in England and Wales (registered no. 3678570).